Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study (Q36611472)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 October 2007

Language	Label	Description	Also known as
English	Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study	scientific article published on 23 October 2007

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

based on heuristic

inferred from title

Joan Carles Galcerán

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Enrique Gallardo

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Jose Luis Gonzalez Larriba

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

A Font

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

B Mellado

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

M Domenech

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

G Catalan

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

J Alfaro

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

A Gonzalez Del Alba

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

M Nogué

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

P Lianes

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

J M Tello

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

0 references

publication date

23 October 2007

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

British Journal of Cancer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

97

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1206-1210

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604030

0 references

Chemotherapy for hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

30 September 2017

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

30 September 2017

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

30 September 2017

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

30 September 2017

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

30 September 2017

Role of COX-2 specific inhibitors in oncogenesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

30 September 2017

Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

30 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

30 September 2017

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

30 September 2017

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

30 September 2017

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

30 September 2017

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

30 September 2017

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

30 September 2017

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

20 September 2018

Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

20 September 2018

Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

20 September 2018

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

20 September 2018

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360463

20 September 2018

Gastric perforation associated with the use of celecoxib

1 reference

https://pubmed.ncbi.nlm.nih.gov/17955053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17955053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17955053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6604030

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955053%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36611472&oldid=1577696957"